The Chief Business Officer of ImmunoPrecise Antibodies (Other OTC: IPATF) is Buying Shares

Today, the Chief Business Officer of ImmunoPrecise Antibodies (IPATFResearch Report), Stefan Lang, bought shares of IPATF for $4,230.

This recent transaction increases Stefan Lang’s holding in the company by 43% to a total of $10.9K. Following Stefan Lang’s last IPATF Buy transaction on November 18, 2019, the stock climbed by 0.6%.

See today’s analyst top recommended stocks >>

Based on ImmunoPrecise Antibodies’ latest earnings report for the quarter ending January 31, the company posted quarterly revenue of $4.03 million and GAAP net loss of -$625,837. In comparison, last year the company earned revenue of $2.7 million and had a GAAP net loss of $1.19 million. Currently, ImmunoPrecise Antibodies has an average volume of 76.40K. The company has a one-year high of $1.52 and a one-year low of $0.23.

The insider sentiment on ImmunoPrecise Antibodies has been positive according to 32 insider trades in the past three months. This sentiment is slightly higher than the average sentiment of company insiders in this sector.

Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

ImmunoPrecise Antibodies Ltd. engages in the provision of integrated antibody solutions. It services include human monoclonals, hybridoma development, rabbit monoclonals, b-cell select, phage display, cryostorage, hybridoma sequencing, antibody generation, anti-body purification, polyclonal production, and peptide production. The company was founded by Robert Beecroft in 1989 and is headquartered in Victoria, Canada.